In this study, researchers aimed to determine whether overall survival is superior with first-line CDK4/6i use compared to second-line use in HR-positive, HER-negative advanced breast cancer.

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, HER2-negative metastatic breast cancer. Phase 2 results reveal median ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or death by 30% in ER-positive, HER2-negative early breast cancer. The ...

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast ...

“Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...